KalVista Pharmaceuticals (KALV) Operating Expenses (2014 - 2025)

KalVista Pharmaceuticals (KALV) has 12 years of Operating Expenses data on file, last reported at $60.4 million in Q3 2025.

• For the quarter ending Q3 2025, Operating Expenses rose 36.68% year-over-year to $60.4 million; the trailing twelve-month figure through Jul 2025 stood at $161.3 million (up 3.67% YoY), and the FY2025 full-year result was $188.0 million, up 33.86% from the prior year.
• Operating Expenses climbed to $60.4 million in Q3 2025, from $55.0 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $60.4 million in Q3 2025 to a low of $12.7 million in Q1 2021.
• A 5-year average of $32.5 million and a median of $28.0 million in 2023 frame the typical range for Operating Expenses.
• Across the five-year window, Operating Expenses dropped 11.5% in 2021 and surged 110.82% in 2022, its largest moves.
• Tracing KALV's Operating Expenses over 5 years: stood at $23.6 million in 2021, then grew by 9.66% to $25.9 million in 2022, then advanced by 14.92% to $29.7 million in 2023, then jumped by 54.01% to $45.8 million in 2024, then surged by 31.92% to $60.4 million in 2025.
• Business Quant data shows KALV's Operating Expenses at $60.4 million in Q3 2025, $55.0 million in Q2 2025, and $45.8 million in Q4 2024.